DSIP
Also known as: Delta Sleep-Inducing Peptide · Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
A nonapeptide originally isolated from the cerebral venous blood of sleeping rabbits, studied for sleep modulation, stress resilience, and indirect cognitive effects.
DSIP is a nonapeptide that modulates slow-wave sleep and HPA-axis stress response; used in sleep, opioid-withdrawal, and stress-resilience research protocols.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Sleep & Recovery
- Half-life
- Short plasma half-life (under 10 min); functional effects persist longer
- Formula
- C₃₅H₄₈N₁₀O₁₅
- Weight
- 848.81 g/mol
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Section 1
Overview
Delta Sleep-Inducing Peptide (DSIP) is a small endogenous nonapeptide originally isolated in 1977 from the cerebral venous blood of rabbits during electrically induced delta-wave sleep. It is one of the earliest 'sleep peptides' to enter the research literature and remains a tool compound for studying the relationship between sleep architecture, stress, and cognition.
Although its name implies a primary role in inducing slow-wave (delta) sleep, the published mechanistic picture is more nuanced: DSIP appears to act more broadly as a stress-resilience and circadian-modulating peptide, with sleep effects that are real but often more subtle and context-dependent than the name suggests.
In research contexts, DSIP is studied alongside cognitive peptides because sleep quality — particularly slow-wave and REM consolidation — is causally upstream of long-term memory formation. Improved sleep architecture is one plausible indirect mechanism for cognitive effects.
Section 2
Discovery & History
- Isolated by Schoenenberger and Monnier in 1977 from cerebral venous blood of sleeping rabbits.
- Synthesised and characterised in the following decades by multiple European research groups.
- Studied in human research for sleep onset, sleep architecture, opioid withdrawal, and stress resilience.
- Remains a research peptide; no major clinical authorisations.
Section 3
Mechanism of Action
- 1Modulation of hypothalamic-pituitary-adrenal (HPA) axis activity — reduction of stress-induced corticotropin-releasing hormone release from the paraventricular nucleus and downstream ACTH / cortisol / corticosterone attenuation in research models.
- 2Influence on slow-wave sleep architecture in some — though not all — research conditions, with the effect most consistent in stress-perturbed or sleep-deprived baselines rather than in already-consolidated sleep.
- 3Antioxidant effects in CNS tissue under stress conditions — measurable reductions in lipid peroxidation markers and preserved endogenous antioxidant enzyme activity in stress-injury models.
- 4Modulation of opioid peptide release contributing to the studied role in opioid-withdrawal research, plausibly via enkephalin and endorphin system interactions that overlap with — but are distinct from — the direct-agonist effect at opioid receptors.
- 5Possible direct effects on thalamocortical oscillatory activity, particularly the delta-generating circuit, providing a mechanism for the slow-wave-sleep modulation that separates DSIP from broader stress-axis modulators.
- 6Interaction with the glutamate-GABA balance in the reticular thalamic nucleus, with reports of increased inhibitory tone at the network scale rather than direct receptor binding.
- 7Immunomodulatory effects — measurable normalisation of stress-perturbed cytokine profiles that parallel the pattern seen with Selank, indicating a possible shared upstream stress-response modulation.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Reduced stress-axis activation in animal stress paradigms — the most-replicated preclinical finding for DSIP and the plausible mechanistic root of many of the downstream effects.
- 2Improvements in subjective sleep quality in early human research, with polysomnographic data showing modest increases in slow-wave sleep duration in some but not all study populations.
- 3Studied utility in opioid withdrawal protocols — Russian addiction-medicine literature reports reductions in withdrawal-symptom severity and improved detoxification tolerability when DSIP is added to the standard regime.
- 4Indirect cognitive effects via improved sleep consolidation — the sleep-cognition link is well-established and DSIP's sleep-architecture effects give it a plausible if indirect nootropic angle.
- 5Generally well-tolerated tolerability profile in published research, with adverse-event rates comparable to placebo across the human studies published to date.
- 6Reported effects on hypertensive stress responses — modest reductions in stress-induced blood-pressure spikes in early cardiovascular research.
- 7Neuroprotective effects in ischaemic and excitotoxic injury models, plausibly downstream of the stress-axis and antioxidant mechanisms.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / intranasal (research) | Microgram-range in research protocols | Typically once daily, often pre-sleep | Short courses |
Note: No standardised human protocol exists in Western clinical practice.
Section 6
Administration Routes
- Subcutaneous — the reference route in the older Russian and European clinical research on DSIP; typically administered as a single evening dose in sleep-relevant protocols.
- Intranasal in some contemporary research protocols, exploiting the nose-to-brain route familiar from the Semax/Selank programme.
- Intramuscular administration is used in some clinical and animal work where injection-volume constraints are relaxed.
- Oral administration is not viable — the nonapeptide is efficiently degraded by gastrointestinal proteases and undergoes complete first-pass metabolism.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in research at studied doses — the tolerability profile is one of DSIP's clearer positive features across the older sleep-research literature.
- · Occasional mild headache or sleep-onset alteration in the initial 1–2 doses; typically transient.
- · Rare reports of transient morning grogginess in intranasal-administered subjects, resolving within 30–60 minutes of waking.
- · Mild injection-site reactions in the subcutaneous route — local redness or transient tenderness that resolves without intervention.
- · Occasional vivid or unusual dreaming, consistent with the modulation of REM architecture reported in the polysomnographic literature.
Rare / theoretical
- · Long-term safety data is limited — most of the published human clinical work is short-course, and chronic-use safety beyond several weeks is not well-characterised.
- · Possible pharmacodynamic interaction with HPA-axis-modulating medications (glucocorticoids, mineralocorticoid antagonists) — theoretical rather than documented.
- · Theoretical interaction with sleep-active pharmaceuticals (Z-drugs, benzodiazepines, orexin antagonists) that share the sleep-architecture endpoint via different mechanisms.
- · Isolated case reports of transient blood-pressure variability during acute administration — the antihypertensive-stress effect can occasionally exceed the intended magnitude.
Contraindications
- · Not approved for human use in the United Kingdom or under a centralised EMA authorisation — DSIP is a research chemical here.
- · Pregnancy and lactation — no controlled human data.
- · Concomitant use of sleep-active hypnotics without a specific research rationale — theoretical additive effect on sleep architecture.
- · Acute severe HPA-axis pathology (Addisonian or Cushingoid states) — the HPA-modulating effect is not characterised in these baselines.
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the United Kingdom. Research chemical only.
European Union
Not approved by the EMA.
Section 9
Clinical Studies Summary
DSIP and slow-wave sleep architecture
Classic European polysomnographic study reporting modest but statistically significant increases in slow-wave sleep duration and reduced sleep-onset latency in subjects receiving intravenous DSIP versus placebo. The magnitude of the sleep-architecture effect was greater in subjects with disturbed baseline sleep than in normal-sleepers, consistent with the interpretation of DSIP as a modulator rather than an inducer.
DSIP in opioid withdrawal
Russian addiction-medicine trial reporting significant reduction in Objective Opiate Withdrawal Scale severity scores in subjects receiving adjunct intranasal DSIP during opioid detoxification, with the effect most pronounced on autonomic and sleep-quality subscales rather than on craving or acute somatic symptoms.
Read studyDSIP and HPA-axis stress response
Preclinical endocrinology study demonstrating attenuation of stress-induced corticosterone elevations following DSIP administration in rodent restraint-stress and forced-swim paradigms, providing molecular support for the interpretation of DSIP as a stress-axis modulator with sleep-architecture effects downstream of the stress-attenuation.
DSIP polysomnographic characterisation in insomnia
Small-N polysomnographic trial in a chronic-insomnia population reporting reduced wake-after-sleep-onset (WASO) and increased slow-wave sleep proportion following a 10-day course of intranasal DSIP; the study is limited by sample size and open-label design.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing DSIP for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain DSIP from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.